Comparison
Rapastinel vs Memantine
Peptide LTP rewiring (rapastinel) versus steady-state NMDA modulation (memantine).
Rapastinel
NMDA Glycine-Site Partial Agonist
Memantine
NMDA Receptor Antagonist
Effectiveness Profile
At a Glance
| Rapastinel | Memantine | |
|---|---|---|
| Type | Nootropic | Nootropic |
| Legal status | Research | Rx-Only |
| Half-life | 7–10 minutes (plasma); pharmacodynamic effect persists days to weeks | 60–80 hours |
| Preferred route | IV | Oral |
| Dose frequency | weekly | once-daily |
| Beginner dose | 1–3 mg | 2.5–5 mg |
| Intermediate dose | 3–5 mg | 10–20 mg |
| Advanced dose | 5–10 mg | 20–30 mg |
| Cycle length | 1–8 wks | 4–52 wks |
| Bioavailability | 100% | 100% |
| Time to peak | 0.03h | 5h |
| Active duration | 168h | 24h |
| Storage | Lyophilized: -20°C long-term, 2–8°C short-term. Reconstituted: 2–8°C, use within 14 days. | Room temperature, 20–25°C, in a dry sealed container away from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Rapastinel wins for acute, rapid-onset synaptic plasticity effects; deep anhedonia rescue; zero long-term cognitive or urogenital baggage; and a side-effect profile that's clean even at high-effective doses. Mechanistically ideal for users chasing ketamine-tier mood and cognition benefits minus dissociation or dependency.
Memantine wins for low-maintenance, orally-administered NMDA antagonism; sustainable dosing in long-term protocols for stimulant or kratom tolerance; slow titration flexibility; and proven synergy with SSRIs in OCD-spectrum scenarios. Its oral bioavailability, week-long half-life, and benign side effect footprint make it a staple for chronic neuroprotection and tolerance attenuation, though it lacks the rapid, high-impact synaptic effects seen with rapastinel.
Pick A or B?
Pick Rapastinel if:
- The protocol aims for rapid, profound rescue of mood or anhedonia (e.g. post-SSRI, anabolic or post-competition crashes)
- A one-off or pulsed intervention for cognitive reset or LTP upregulation is desired
- Ketamine-like synaptic effects are appealing, but without dissociation or dependency liability
- Side-effect minimization is critical (even at high doses)
- IV route is not a dealbreaker for the research setup
Pick Memantine if:
- Chronic stimulant or kratom tolerance is creeping, requiring ongoing NMDA tone suppression
- The research aims for steady-state, oral dosing with slow titration—no IV setup needed
- SSRI augmentation for OCD/BDD-adjacent rumination is a goal
- There is interest in long-term neuroprotection or glutamatergic stabilization
- Minimal acute subjective effects are preferable (gradual buildup, no acute buzz)